June 13, 2024

Minaris Regenerative Medicine Implements Manufacturing Execution System Werum PAS-X MES

Lüneburg and Ottobrunn, Germany, June 13, 2024 Minaris Regenerative Medicine GmbH (Minaris), a leading contract development and manufacturing organization for cell and gene therapies, has implemented a digital Manufacturing Execution System (MES), the newest version of Werum PAS-X MES by Körber, at its German site in Ottobrunn near Munich. By doing so, Minaris is converting its production management to digital processes and following the right first time principle for highest quality. 

With the MES, already parallel to production, batches can be documented paperless, checked and released within the shortest possible time. “Through the review by exception concept, we offer our customers efficient processes and more agility in a cost-effective manner”, said Renate Sporrer, COO of Minaris Regenerative Medicine GmbH. “We will benefit from operational advantages such as faster batch releases, as well as time and cost savings. Werum PAS-X MES is an important building block for our customers to shorten their time to market.” The status of equipment can also be controlled electronically. In addition, the digital production management system enables Minaris to make a wide range of process information for clients efficiently and quickly available.

Körber's latest version Werum PAS-X MES 3.3 covers all of Minaris’ requirements, which allowed Minaris to implement the software without any customization. By using the "Continuous Evolution Stream" support model, Minaris ensures that the MES system can be updated every six months. The company will regularly benefit from new features as soon as they are released. Via an interface, PAS-X MES integrates the Enterprise Resource Planning (ERP) system into the production IT infrastructure.

 

About Körber

Körber is an international technology group with about 12,000 employees at more than 100 locations worldwide. At the Körber Business Area Pharma we are delivering the difference along the pharma value chain with our unique portfolio of integrated solutions. With our software solutions we help drug manufacturers to digitalize their pharmaceutical, biotech and cell & gene therapy production. The Werum PAS-X MES Suite is recognized as the world’s leading Manufacturing Execution System for pharma, biotech and cell & gene. Our Werum PAS-X Savvy Suite accelerates product commercialization with data analytics and AI solutions and uncovers hidden business value.
www.koerber-pharma.com

Contact
Dirk Ebbecke
Körber Business Area Pharma
Head of Product Marketing
T: +49 4131 8900-0
E-Mail: dirk.ebbecke@koerber.com

 

About Minaris Regenerative Medicine

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years’ experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply life-changing therapies to patients globally. Minaris Regenerative Medicine is part of the Resonac Group. 
For more information, please visit www.rm.minaris.com 

 

Contact
Dr. Almut Windhager
Senior Manager Communications
Minaris Regenerative Medicine GmbH
E-Mail: press@rm.minaris.de
Phone: +49 (0)89 700 9608-0

Media Contact Info:

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, fomerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. have been renamed Minaris Regenerative Medicine and are part of the Resonac Group.

Stay up to date
on the latest news